BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 31253745)

  • 1. Multiparametric
    Leithner D; Helbich TH; Bernard-Davila B; Marino MA; Avendano D; Martinez DF; Jochelson MS; Kapetas P; Baltzer PAT; Haug A; Hacker M; Tanyildizi Y; Morris EA; Pinker K
    J Nucl Med; 2020 Jan; 61(1):20-25. PubMed ID: 31253745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multiparametric [
    Leithner D; Horvat JV; Bernard-Davila B; Helbich TH; Ochoa-Albiztegui RE; Martinez DF; Zhang M; Thakur SB; Wengert GJ; Staudenherz A; Jochelson MS; Morris EA; Baltzer PAT; Clauser P; Kapetas P; Pinker K
    Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1878-1888. PubMed ID: 31197455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative Assessment of Breast Parenchymal Uptake on 18F-FDG PET/CT: Correlation with Age, Background Parenchymal Enhancement, and Amount of Fibroglandular Tissue on MRI.
    Leithner D; Baltzer PA; Magometschnigg HF; Wengert GJ; Karanikas G; Helbich TH; Weber M; Wadsak W; Pinker K
    J Nucl Med; 2016 Oct; 57(10):1518-1522. PubMed ID: 27230924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preliminary analysis: Background parenchymal 18F-FDG uptake in breast cancer patients appears to correlate with background parenchymal enhancement and to vary by distance from the index cancer.
    Kim E; Mema E; Axelrod D; Sigmund E; Kim SG; Babb J; Melsaether AN
    Eur J Radiol; 2019 Jan; 110():163-168. PubMed ID: 30599855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does breast MRI background parenchymal enhancement indicate metabolic activity? Qualitative and 3D quantitative computer imaging analysis.
    Mema E; Mango VL; Guo X; Karcich J; Yeh R; Wynn RT; Zhao B; Ha RS
    J Magn Reson Imaging; 2018 Mar; 47(3):753-759. PubMed ID: 28646614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved differentiation of benign and malignant breast tumors with multiparametric 18fluorodeoxyglucose positron emission tomography magnetic resonance imaging: a feasibility study.
    Pinker K; Bogner W; Baltzer P; Karanikas G; Magometschnigg H; Brader P; Gruber S; Bickel H; Dubsky P; Bago-Horvath Z; Bartsch R; Weber M; Trattnig S; Helbich TH
    Clin Cancer Res; 2014 Jul; 20(13):3540-9. PubMed ID: 24963052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic accuracy of (18)F-FDG PET/CT compared with that of contrast-enhanced MRI of the breast at 3 T.
    Magometschnigg HF; Baltzer PA; Fueger B; Helbich TH; Karanikas G; Dubsky P; Rudas M; Weber M; Pinker K
    Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1656-1665. PubMed ID: 26121928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apparent diffusion coefficient mapping using diffusion-weighted MRI: impact of background parenchymal enhancement, amount of fibroglandular tissue and menopausal status on breast cancer diagnosis.
    Horvat JV; Durando M; Milans S; Patil S; Massler J; Gibbons G; Giri D; Pinker K; Morris EA; Thakur SB
    Eur Radiol; 2018 Jun; 28(6):2516-2524. PubMed ID: 29330631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic changes in breast cancer on dual-time-point
    Kim HO; Kim BS; Kang SY; Bang JI; An J; Kim JH; Yoon HJ
    Ann Nucl Med; 2020 Dec; 34(12):942-951. PubMed ID: 32974848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Background ¹⁸F-FDG uptake in positron emission mammography (PEM): correlation with mammographic density and background parenchymal enhancement in breast MRI.
    Koo HR; Moon WK; Chun IK; Eo JS; Jeyanth JX; Chang JM; Cho N; Kang KW
    Eur J Radiol; 2013 Oct; 82(10):1738-42. PubMed ID: 23806533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical roles of breast 3T MRI, FDG PET/CT, and breast ultrasound for asymptomatic women with an abnormal screening mammogram.
    Chou CP; Peng NJ; Chang TH; Yang TL; Hu C; Lin HS; Huang JS; Pan HB
    J Chin Med Assoc; 2015 Dec; 78(12):719-25. PubMed ID: 26364959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiparametric evaluation of breast lesions using PET-MRI: initial results and future perspectives.
    Bitencourt AGV; Lima ENP; Chojniak R; Marques EF; Souza JA; Andrade WP; Guimarães MD
    Medicine (Baltimore); 2014 Nov; 93(22):e115. PubMed ID: 25396329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diffusion-Weighted Imaging With Apparent Diffusion Coefficient Mapping for Breast Cancer Detection as a Stand-Alone Parameter: Comparison With Dynamic Contrast-Enhanced and Multiparametric Magnetic Resonance Imaging.
    Pinker K; Moy L; Sutton EJ; Mann RM; Weber M; Thakur SB; Jochelson MS; Bago-Horvath Z; Morris EA; Baltzer PA; Helbich TH
    Invest Radiol; 2018 Oct; 53(10):587-595. PubMed ID: 29620604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Automatic segmentation and classification of breast lesions through identification of informative multiparametric PET/MRI features.
    Vogl WD; Pinker K; Helbich TH; Bickel H; Grabner G; Bogner W; Gruber S; Bago-Horvath Z; Dubsky P; Langs G
    Eur Radiol Exp; 2019 Apr; 3(1):18. PubMed ID: 31030291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential [
    Andrzejewski P; Wengert G; Helbich TH; Magometschnigg H; Georg D; Hacker M; Baltzer P; Clauser P; Kapetas P; Georg P; Wadsak W; Pinker K
    Contrast Media Mol Imaging; 2019; 2019():1307247. PubMed ID: 30728757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of background parenchymal enhancement levels on the diagnosis of contrast-enhanced digital mammography in evaluations of breast cancer: comparison with contrast-enhanced breast MRI.
    Yuen S; Monzawa S; Gose A; Yanai S; Yata Y; Matsumoto H; Ichinose Y; Tashiro T; Yamagami K
    Breast Cancer; 2022 Jul; 29(4):677-687. PubMed ID: 35220511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of ¹⁸F-FDG PET/MRI, ¹⁸F-FDG PET/CT, MRI, and CT in whole-body staging of recurrent breast cancer.
    Sawicki LM; Grueneisen J; Schaarschmidt BM; Buchbender C; Nagarajah J; Umutlu L; Antoch G; Kinner S
    Eur J Radiol; 2016 Feb; 85(2):459-65. PubMed ID: 26781152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of combined BI-RADS assessment using mammography and sonography for evaluation of incidental hypermetabolic lesions in the breast on 18F-FDG PET-CT.
    Lim S; Lee EH; Park JM; Chang YW; Kim HH; Jeong SH
    Acta Radiol; 2013 Dec; 54(10):1117-24. PubMed ID: 23864064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ionising radiation-free whole-body MRI versus (18)F-fluorodeoxyglucose PET/CT scans for children and young adults with cancer: a prospective, non-randomised, single-centre study.
    Klenk C; Gawande R; Uslu L; Khurana A; Qiu D; Quon A; Donig J; Rosenberg J; Luna-Fineman S; Moseley M; Daldrup-Link HE
    Lancet Oncol; 2014 Mar; 15(3):275-85. PubMed ID: 24559803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of the breast radiologist in evaluation of breast incidentalomas detected on 18-fludeoxyglucose positron emission tomography/CT.
    Dunne RM; O'Mahony D; Wilson G; McDermott R; O'Keeffe SA
    Br J Radiol; 2013 Jun; 86(1026):20130034. PubMed ID: 23568361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.